♥ HF Guideline NavigatorESC 2026

8 › 8.2 › 8.2.3

8.2.3 Heart transplantation

Pages 57–58 · open in PDF

Recommendations in this section

  • Class ILevel CHeart transplantation is recommended in selected patients with advanced HF refractory to FMT and GDIT, and without contraindications, to improve QoL and survival.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 57 · PDF

to study strategies of early LVAD implantation vs prolonged medical treatment: Early-VAD (NCT02387112),614 SweVAD,615 AMBU-VAD (NCT04768322), and TEAM-HF (NCT06526195). Histological examination of heart tissue after LVAD implantation or transplantation can identify potentially treatable or genetic causes of HF and is valuable for family screening and determining potential for myocardial recovery in LVAD patients.616–619

Table 16 Indications and contraindications for implantation of a left ventricular assist device Indicationsa HF with severely reduced LVEF and one of the following: • INTERMACS 1–2 with neurological and other end-organ recovery but no cardiac recovery on temporary MCS OR

Recommendation Table 13 — Recommendations for durable mechanical circulatory support in advanced heart failure (see Evidence Table 74)

OR • Severe symptoms and signs (NYHA class III/IV; INTERMACS >4) despite optimal FMT and GDIT, and at least one of the following: ⚬ Unable to exercise due to HF or, if able to perform CPET, with

pVO2 <12–14 mL/kg/min and/or <50% predicted value.

Durable MCS (LVAD) is recommended in

⚬ End-organ dysfunction (worsening kidney and/or hepatic function, group 2 pulmonary hypertension, cardiac cachexia)

selectedc patients with advanced HFrEF, despite FMT and GDIT, as BTT, BTC, BTR, or as destination therapy to improve symptoms and

due to reduced perfusion as indicated by cardiac index ≤2 L/ 2

min/m despite euvolaemic or therapy-resistant hypervolaemic status.

reduce the risk of death.604,611,613,620,621 Histopathological examination of explanted

⚬ Repeated HFH within the previous 12 months without an

surgery should be considered in patients with non-ischaemic HF to identify an aetiological

Contraindications Absolute:

diagnosis that may be treatable or facilitate

• Severe right ventricular dysfunction despite euvolaemic status • Severe irreversible end-organ (kidney and/or liver) disease

family screening.616,618 BTC, bridge to candidacy; BTR, bridge to recovery; BTT, bridge to transplantation; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LVAD, left ventricular assist device; MCS, mechanical circulatory support. a Class of recommendation. b Level of evidence. c Eligibility criteria are reported in Table 16.

• Severe irreversible neurological disease • Severe pulmonary disease • Contraindication to long-term oral anticoagulation • Medical non-adherence and/or other psychosocial limitations • Insufficient social supports to achieve compliant care in the outpatient setting • Psychological instability that jeopardizes proper follow-up and intensive therapeutic regime after implantation

8.2.3. Heart transplantation

Relative: • Obesity or malnutrition • Musculoskeletal disease that impairs rehabilitation • Malignancy (depending on type and prognosis) • Systemic infection • Alcohol or substance abuse within the past 6 months, or active smoking • Impaired cognitive function • Frailty CPET, cardiopulmonary exercise testing; HF, heart failure; HFH, heart failure hospitalization; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; NYHA, New York Heart Association; pVO2, peak oxygen consumption; RHC, right heart catheterization. a Indication by transplantation centre includes assessment of HF severity by RHC and/or CPET.

therapy in patients with advanced HF. REMATCH showed lower all-cause death with a previous type of LVAD therapy (HeartMate XVE) compared with medical treatment. However, mortality rates at 2 years were high in both arms.611 Other studies have not been randomized or compared different devices or post-implant strategies.604,606,607,610,612,613 Prospective RCTs have been initiated

• Severe peripheral arterial disease

Heart transplantation, although never evaluated in RCTs, remains the gold-standard treatment for advanced HF in the absence of contraindications. Post-transplant 1-year survival is 80%–90% and median survival is around 12.5 years.622,623 Transplantation significantly improves QoL and functional status. The main challenge after heart transplantation is the balance between efficacy and side effects of immunosuppression. Organ donor shortage remains the main limitation. Several countries have now started donation after circulatory death programmes, besides donation after brain death, with comparable mid-term results624,625 and, as a result, the numbers of heart transplantations have increased. Nevertheless, careful recipient selection remains essential, based on pre-transplant and post-transplant life expectancy (both influenced by pre-operative status and comorbidities). The main indications and contraindications for heart transplantation are listed in Table 17.580 Although patients younger than 65 years of age might be more appropriate candidates due to their overall life expectancy, most programmes accept patients up to 70 years of age, and biological age as well as chronological age must be taken into account. Surgical complexity [previous sternotomies, mediastinal radiation, adult congenital heart disease (ACHD)] should also be considered. The decision pathway to transplantation or LVAD is rarely straightforward and is unique to each patient.

heart tissue from LVAD or heart transplantation

obvious precipitating cause.

Page 58 · PDF

8.2.4. Symptom control and end-of-life care

Table 17 Indications and contraindications for heart transplantation

Advanced HF and no other therapeutic option (except for durable MCS as BTT) Absolute contraindications Inability to comply with the therapeutic regimen (e.g. dementia) Serious comorbidities with poor prognosis, not reversible with heart transplantation Other contraindications Active infectionb Severe peripheral arterial or cerebrovascular disease Elevated pulmonary vascular resistance (if pharmacologically irreversible)c Cancerd Irreversible liver dysfunction (cirrhosis) or irreversible kidney dysfunctione Systemic disease with multiorgan involvement BMI >35 kg/m2 or severe cachexia

Alcohol or substance abuse or active smoking within the past 6 months Psychological instability Insufficient social support to achieve compliant care in the outpatient setting

Eligibility for each option may change according to the specific conditions of each patient, which may also change over time. Some younger patients prefer to remain on LVAD for a prolonged period, rather than proceeding to transplantation immediately, to increase the potential number of life years gained. Other factors not related to the patient, such as average time on the heart transplantation waiting list, the centre’s surgical experience, and resources, can also influence decision-making.

Precipitating factors for AF – e.g. hyperthyroidism, toxic agents (e.g. including alcohol), valvular heart diseases, infection, diabetes, uncontrolled hypertension, obesity, sleep disorders, and volume overload – should be routinely identified and appropriately managed. Diuretic therapy is indicated to relieve congestion and may increase the chances of restoring sinus rhythm by reducing filling pressures and ventricular rate.

to FMT and GDIT, and without contraindications, to improve QoL and 622,626

FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; QoL, quality of life. a Class of recommendation. b Level of evidence. c Eligibility criteria are reported in Table 17.

Heart transplantation is recommended in selectedc patients with advanced HF refractory

9.1.1. Atrial fibrillation

9.1.1.1. Identification of triggers and risk factor management

Recommendation Table 14 — Recommendations for heart transplantation (see Evidence Tables 75 and 76) Classa

9.1. Arrhythmias and conduction disturbances Heart failure and AF frequently coexist, with AF occurring in more than half of patients with HF, and HF occurring in more than one-third of patients with AF. The prevalence of AF is slightly higher in patients with HFpEF compared with HFrEF.195,628–631 The two conditions are deeply interrelated with shared risk factors and pathophysiological mechanisms. The coexistence of HF and AF is associated with a high risk of death, HFH, and stroke regardless of LVEF.195,628–631 HF induced by AF appears to have a more favourable outcome than HF causing AF.13,632 The management of patients with HF and AF include identification of triggers, prevention of embolic events, management of HF, and rate or rhythm control of AF.

BMI, body mass index; BTT, bridge to transplantation; CPET, cardiopulmonary exercise testing; HF, heart failure; LVAD, left ventricular assist device; MCS, mechanical circulatory support; RHC, right heart catheterization. a Indication by heart transplantation centre includes assessment of HF severity by RHC and/or CPET. b Active infection is a relative contraindication to transplantation, but infected LVAD may be an indication. c LVAD as bridge to candidacy should be considered. d Highly selected cases may be eligible, to be discussed with an oncologist. e Combined heart–liver or heart–kidney transplantation may be considered.

9. Cardiovascular comorbidities

9.1.1.2. Prevention of embolic events Oral anticoagulation is recommended in patients with HF and AF to reduce the risk of thromboembolism, according to the CHA2DS2-VA score (Table 18).118,633–635 However, patients with HCM and CA are at higher risk of thromboembolism irrespective of CHA2DS2-VA score, and anticoagulation is recommended for all these patients with AF.636–642 In the absence of mechanical prosthetic heart valves and/or moderate

Advance care planning is recommended in parallel to advanced HF treatments to determine goals of care and improve QoL along the disease trajectory.627 For indications and the core components of end-of-life care, see Supplementary data online, Table S20. End-of-life care in advanced HF focuses on symptom management (including breathlessness, pain, and anxiety and depression), patient comfort, and maintaining QoL ensuring personalized, compassionate care. It involves clear communication, shared decisionmaking, and integrating palliative or hospice care to support both the patient and their family. For further details on symptom management, see Supplementary data online, Section S5.2.3. Patients on durable MCS may request withdrawal of lifesustaining treatments because these are no longer consistent with their goals of care, because of poor QoL or newly developed serious comorbidities such as cancer. The MCS may be deactivated after careful evaluation of the patient’s wish and by, or under the supervision of, a specialized team. This decision has to take national laws into account. For details regarding follow-up in patients with advanced HF see section 11.6.2 and Recommendation Table 26.